TScan Therapeutics Files 8-K on Shareholder Votes
Ticker: TCRX · Form: 8-K · Filed: Jul 2, 2025 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing
TL;DR
TScan Therapeutics filed an 8-K on shareholder votes as of June 30th.
AI Summary
TScan Therapeutics, Inc. filed an 8-K on July 2, 2025, reporting on matters submitted to a vote of security holders as of June 30, 2025. The filing details the company's corporate structure and its principal executive offices located at 830 Winter Street, Waltham, Massachusetts.
Why It Matters
This filing indicates a formal process of shareholder engagement and decision-making, which is a standard corporate governance event.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding shareholder votes, not indicating any immediate financial or operational risks.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- June 30, 2025 (date) — Date of earliest event reported
- July 2, 2025 (date) — Date of Report
- 830 Winter Street, Waltham, Massachusetts (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of TScan Therapeutics' security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was as of June 30, 2025.
What is the principal executive office address for TScan Therapeutics, Inc.?
The principal executive offices are located at 830 Winter Street, Waltham, Massachusetts, 02451.
What is TScan Therapeutics, Inc.'s SEC file number?
TScan Therapeutics, Inc.'s SEC file number is 001-40603.
What is the Standard Industrial Classification (SIC) code for TScan Therapeutics, Inc.?
The Standard Industrial Classification code for TScan Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding TScan Therapeutics, Inc. (TCRX).